Clinical Trial Update: Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacytidine plus chidamide for relapsed and refractory angioimmunoblastic T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• azacytidine (azacitidine)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: UNKNOWN